Accustem Sciences Business Summary

AccuStem Sciences Inc. (ACUT) is a clinical-stage diagnostics company that generates revenue through the development and commercialization of proprietary genomic tests designed to optimize oncology care. The company’s business model is centered on its "stemness" biology platform, which interrogates the relationship between stem cells and cancer recurrence to provide prognostic insights. Its primary business segments include breast cancer diagnostics, led by the StemPrintER assay for predicting distant recurrence in ER+/HER2- patients, and lung cancer screening via the MicroRNA Signature Classifier (MSC) test, which is slated for a full clinical launch in early 2026. AccuStem operates within a highly competitive molecular diagnostics landscape, contending with direct peers such as TransCode Therapeutics, Phio Pharmaceuticals, BioRestorative Therapies, and Edesa Biotech. The company distinguishes itself by focusing on unmet clinical needs in cancer screening and treatment monitoring, aiming to capture a share of the estimated $6.3 billion annual market for oncology diagnostics. AccuStem was founded in 2020 as a strategic spin-off from Tiziana Life Sciences to monetize its genomic signature assets. The leadership team is headed by CEO Wendy Blosser, a commercial veteran with over 25 years of experience who previously served as Chief Commercial Officer at Agendia and Biodesix. She is supported by Chief Business Officer Joe Flanagan, also formerly of Agendia, and Chief Financial Officer Keeren Shah, who brings extensive financial expertise from her tenure at Tiziana and OKYO Pharma. The company’s strategic direction is heavily influenced by Executive Chairman Gabriele Cerrone, a prolific biotech entrepreneur and the company’s largest shareholder. The board of directors includes notable industry figures such as Sean McDonald and John Brancaccio, providing a pedigree of successful commercialization in the diagnostics and surgical sectors. AccuStem maintains a strategic partnership with EmeritusDX for laboratory processing and CLIA-certified clinical deployment.